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A 67 year old male at a regular checkup underwent esophagogastroduodenoscopy. On performing esophagogastroduodenoscopy, a 
lesion about 1.2 cm depressed was noted at the gastric angle. The pathology of the biopsy specimen revealed a well-differentiated ad-
enocarcinoma. On performing an abdominal computed tomography (CT) scan & positron emission tomography-computed tomography 
(PET-CT) scan, no definite evidence of gastric wall thickening or mass lesion was found. However, lymph node enlargement was found 
in the left gastric and prepancreatic spaces. This patient underwent laparoscopic assisted distal gastrectomy and D2 lymph node dissec-
tion. On final examination, it was found out that the tumor had invaded the mucosal layer. The lymph node was a metastasized large 
cell neuroendocrine carcinoma with an unknown primary site. The patient refused chemotherapy. He opted to undergo a close follow-
up. At the postoperative month 27, he had a focal hypermetabolic lesion in the left lobe of the liver that suggested metastasis on PET-CT 
scan. He refused to undergo an operation. He underwent a radiofrequency ablation.
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Introduction 
Cancer of unknown primary site (CUP) represent a hetero-
geneous group of metastatic tumors for which a standardized di-
agnostic work-up fails to identify the site of origin at the time of 
diagnosis and account for 3~5% of all malignancies.(1) Poorly dif-
ferentiated large cell neuroendocrine carcinoma (LCNEC) comprise 
a rare and still seldom reported subset of neuroendocrine tumors. 
Here, we present a rare case of LCNEC of unknown primary site, 
which was detected originally in a lymph node of early gastric can-
cer. 
Case Report
A 67 year old male without any significant past medical his-
tory underwent esophagogastroduodenoscopy during a routine 
check-up. He had no other symptoms. Physical examination was 
unremarkable and laboratory findings showed no abnormalities. On 
esophagogastroduodenoscopy, mild atrophic change with intestinal 
metaplasia was noted at the antrum and body. About 1.2 cm de-
pressed lesion at the angle and about 1.5 cm mildly elevated lesion 
at the posterior wall of the antrum were noted. The pathology of 
the biopsy specimen revealed a well differentiated adenocarcinoma. 
On abdominal computed tomography (CT) scan, there was no 
definite evidence of gastric wall thickening or mass lesion. How-
ever, a lymph node enlargement was found in the left gastric and 
prepancreatic spaces. On positron emission tomography-computed 
tomography (PET-CT) scan, there was no visible hypermetabolic 
activity of proven gastric malignancy. Hypermetabolic activity, 
however, was depicted in the prepancreatic area and the left gas-
tric area that implied metastatic lymphadenopathy (Fig. 1). The Neuroendocrine Tumor of Unknown Primary 
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gastric tumor had invaded the mucosal layer on the endoscopic 
ultrasonography. This patient underwent laparoscopic assisted 
distal gastrectomy and D2 lymph node dissection with Billroth-I 
reconstruction. On the final pathologic examination, there were 
two early gastric cancers (Fig. 2). One tumor was 1.5×1.0 cm, an 
early gastric cancer (EGC) type III lesion at the lower body of the 
stomach. The other was a 1.2×1.0 cm EGC type IIc lesion at the 
angle of the stomach. The tumors were well-differentiated carci-
nomas that invaded the mucosal layer (T1a). Lymph node sections 
showed that the tumor tissue consisted of neoplastic pleomorphic 
large cells with a palisading, trabecula and sinusoid pattern (Fig. 3). 
There were frequent mitoses (more than 20/10 High Power Fields) 
and some necrosis. These cells were positive for CD56, chromo-
granin and synaptophysin on immunohistochemical stains (Fig. 
4). These findings were compatible with large cell neuroendocrine 
carcinomas. The patient recovered well and was discharged on the 
postoperative day 8. The patient refused adjuvant chemotherapy 
and opted to undergo close follow-up. At postoperative month 27, 
he had a focal hypermetabolic lesion in the left lobe of the liver that 
suggested metastasis on PET-CT (Fig. 5). The tumor was 2.3 cm 
Fig. 1. Preoperative abdominal com-
puterd tomography scan (A) and posi-
tron emission tomography-computerd 
tomography (B).
Fig. 2. Th   e resected specimen showed two early gastric cancers. One 
tumor was 1.5×1.0 cm, early gastric cancer (EGC) type III lesion at the 
lower body of the stomach. Th   e other was a 1.2×1.0 cm, EGC type IIc 
lesion at the angle of the stomach.
Fig. 3. Lymph node sections showed that the tumor tissue consisted of 
neoplastic pleomorphic large cells with palisading, trabecula and sinu-
soid pattern (hematoxylin-eosin stain, original magnifi  cation, ×12.5).Kim HY, et al.
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and oval shaped on magnetic resonance imaging of the liver and 
we therefore planned surgery. However, the patient did not want 
surgery, so he had radiofrequency ablation. The tumor cells were 
positive for cytokeratin (CK), CK7, CD56, and synaptophysin, and 
negative for CK20, chromogranin, and HepPar-1 on liver biopsy 
on immunohistochemical stains. There was no procedure-associat-
ed morbidity. He did not want platinum-based chemotherapy that 
required hospitalization, so he is treated with oral fluorouracil based 
chemotherapy.
Discussion
Patients with metastatic CUP present with metastatic disease 
without an established primary site. The majority of patients (80%) 
have systemic metastases of adenocarcinomas or poorly differenti-
ated carcinomas and appear in the poor risk CUP group. Only 20% 
of patients belong to favorable prognosis groups.(2)
Neuroendocrine CUP account for uncommon, diverse tumors 
with variable clinical behavior, predicted by tumor grade or differ-
entiation. These carcinomas probably arise from an occult/clinically 
undetectable primary site in one of several locations such as bron-
chus, pancreas, stomach, colon, rectum and several other sites.(3) 
There are two different clinicopathologic subsets of neuroendo-
crine tumor (NET). 
The first subset includes low-grade or well differentiated tumors 
that are frequently indolent and should be managed similar to ad-
vanced carcinoid tumors. 
The second subset includes high-grade or poorly differentiated 
carcinomas that are rapidly growing and aggressive but responsive 
to platinum based combination chemotherapy. These subsets also 
include small cell and large cell NETs. Poorly differentiated large 
cell NETs are usually not identified by routine hematoxylin and 
eosin light microscopy but require immunohistochemical stains (i.e. 
chromogranin, synaptophysin, etc.) or electron microscopy for their 
diagnosis.(3)
Staining for keratins CK7 and CK20 may suggest indications of 
Fig. 4. Th   e tumor cells of neuroendocrine carcinoma showed positive 
stains for CD56, chromogranin and synaptophysin on immunohisto-
chemical stains (CD56, original magnifi  cation, ×100).
Fig. 5. Postoperative liver magnetic 
resonance imaging (MRI) & positron 
emission tomography-computerd 
tomography (PET-CT) scan. At post-
operative month 27, the patient had a 
focal hypermetabolic lesion in the left   
lobe of the liver that suggested metas-
tasis on PET-CT (B, C). Th   e tumor was 
2.3 cm and oval shaped on MRI over 
the liver (A).Neuroendocrine Tumor of Unknown Primary 
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a possible primary site, and staining for chromogranin A and syn-
aptophysin is needed to profile neuroendocrine differentiation. In 
our case, the lymph nodes were strongly positive for chromogranin, 
synaptophysin, and CD56, and focal positive for CK, but the tumor 
cells of the metastatic liver were positive for CK, CK7, CD56, and 
synaptophysin, and negative for CK20 and chromogranin. The 
CK7+/CK20- phenotype favors the lung, breast or ovarian primary 
carcinoma but the number of false-positives and false-negatives 
makes a definitive diagnosis of a primary site difficult on this basis 
alone.(4-6) In our case, there was a 3~4 mm small nodule on the 
right upper lobe of the lung that suggested granuloma on preopera-
tive chest CT scan and the patient underwent close follow-up for 
more than 2 years. However, we could not find any suspicious le-
sion except a focal hypermetabolic lesion in the left lobe of the liver 
on abdominal CT scan & PET-CT scan.
Hepatic metastases are the most powerful prognosticator of 
survival in patients with NET  regardless of primary site.(7) Besides 
regional lymph nodes, the liver is the predominant site of NET 
metastases. Up to 75% of patients with small bowel NET and 30-
85% of those with tumors localized within the pancreas present 
with liver metastases either at initial evaluation or during the course 
of their disease.(8-10) An additional 5~10% of NET patients 
present with liver metastases with unknown primary tumor site. 
A 13~54% 5 year survival in histological cohorts of patients with 
untreated neuroendocrine liver metastases compared with 75~99% 
in those free of hepatic deposits underlines the unique molecular 
genetics of malignant NET and clearly delineates them from their 
non-endocrine counterparts.(11-14)
The treatment of a NET with liver metastases includes liver re-
section, liver transplantation, radiofrequency ablation, hepatic trans-
catheter arterial embolization, peptide receptor radionuclide ther-
apy, chemotherapy, etc. In our case, the tumor was a single lesion 
that was located in the lateral segment of the liver, and we planned 
surgery. For patients with NET liver metastases and unknown pri-
mary tumor, surgical exploration effectively identifies and resects 
occult primary tumors that are often located in the small intestine. 
Within the gastrointestinal NET, the small intestine is the most 
common site. Computed tomography may be useful in detecting 
mesenteric masses that may result from extension of the primary 
NET or lymph node metastases with associated fibrosis, suggesting 
a small-intestine primary tumor.(15) If the patient had undergone 
surgical exploration, we might have a chance to find a lesion that 
had not shown on abdominal CT scan. However, the patient did 
not want  surgery, so he had radiofrequency ablation. There was no 
procedure-associated morbidity. He did not want platinum-based 
chemotherapy that required hospitalization, so he is being treated 
with oral fluorouracil based chemotherapy. 
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